Lipocurc is under clinical development by SignPath Pharma and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Lipocurc’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Lipocurc overview

Liposomal curcumin is under development for the treatment of metastatic cancer, advanced solid tumors including non-small cell lung carcinoma, prostate cancer, colon cancer, glioblastoma multiforme, mesothelioma,multiple myeloma, sepsis, Parkinson's disease and coronavirus disease 2019 (COVID-19). The drug candidate is administered through intravenous infusion and acts by targeting HDAC. It is a nanoparticle-sized liposomal formulation.

It was also under development for the treatment of psoriasis, pancreatic cancer and Ebola viral infections.

SignPath Pharma overview

SignPath Pharma develops curcumin based drugs to treat cancer and cardiac side effects. The company is investigating its lead products SPP4040, a cancer supportive care drug to reduce cardiomyopathy caused due to cancer chemotherapy; and LipoCurc, a liposomal synthetic curcumin formulation targeting glioblastoma, multiple myeloma, and other cancer indications. It is also evaluating LipoCurc for the treatment of sepsis and COVID-19. SignPath Pharma utilizes CorreQT, its proprietary platform technology to create lipid based drugs that mitigate cardiac side effects. The company works in partnership with labs, hospitals, and other companies in Canada, Europe, the US, and Asia. SignPath Pharma is headquartered in Sandy, Utah, the US.

For a complete picture of Lipocurc’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.